Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for LAURUSLABS.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LAURUSLABS.BO and 80,000+ other tickers.
See exactly how LAURUSLABS.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LAURUSLABS.BO and 80,000+ other tickers.
Operating both domestically in India and internationally, Laurus Labs Limited, through its various subsidiaries, is a diversified pharmaceutical company engaged in the research, development, manufacturing, and commercialization of both active pharmaceutical ingredients (APIs) and finished drug products. The firm produces APIs and advanced intermediates for a broad spectrum of therapeutic areas, including anti-retroviral (ARV), anti-diabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Complementing this, it also develops and manufactures oral…
No recent news available.